HUTCHMED says SAFFRON Phase III trial of savolitinib — osimertinib combo beats chemo in EGFR — mutant NSCLC after osimertinib progression
HUTCHMED flagged new data for savolitinib with osimertinib at ESMO Congress 2026 in Madrid on Oct. 23-27. Results will be presented in future oral sessions from two positive Phase III studies, including a Presidential Symposium slot. SAFFRON showed the chemo-free regimen improved patient outcomes versus platinum-based